MedTrace Logo

Evaluate the Therapeutic Effect of Inhaled Corticosteroid in Asthmatic Children

NCT03487809 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2023-09-21

No results posted yet for this study

Summary

Inhaled corticosteroid (ICS) is considered the first line medication for asthma, however, the therapeutic effect is markedly different even in patients with almost similar clinical manifestations. Our study was designed to explore the clinical and genetic factors that may influence the effectiveness of ICS in asthmatic children.

Conditions

Interventions

DRUG

Budesonide/Cisclesonide

One arm observation study: Duasma 1 puff bid (Budesonide 200mcg bid) or Alvesco 1 puff qd (Ciclesonide 160mcg qd) for participants aged 11 years and younger, Duasma 2 puffs bid (Budesonide 400mcg bid) or Alvesco 1 puff bid(Ciclesonide 160mcg bid) for participants aged 12 years and older

Sponsors & Collaborators

  • Academia Sinica, Taiwan

    collaborator OTHER

  • National Taiwan University Hospital

    lead OTHER

Principal Investigators

  • Yungling Lee, Professor · NTUH

Eligibility

Min Age
5 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-22
Primary Completion
2025-12-31
Completion
2025-12-31
FDA Drug
Yes

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03487809 on ClinicalTrials.gov